MedKoo Cat#: 531334 | Name: WHI-P180
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

WHI-P180 is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.

Chemical Structure

WHI-P180
WHI-P180
CAS#211555-08-7

Theoretical Analysis

MedKoo Cat#: 531334

Name: WHI-P180

CAS#: 211555-08-7

Chemical Formula: C16H15N3O3

Exact Mass: 297.1113

Molecular Weight: 297.31

Elemental Analysis: C, 64.64; H, 5.09; N, 14.13; O, 16.14

Price and Availability

Size Price Availability Quantity
5mg USD 305.00 2 Weeks
25mg USD 750.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
WHI-P180; WHI-P-180; WHI-P 180; WHIP180; WHIP-180; WHIP 180; Janex 3; Janex-3; Janex3;
IUPAC/Chemical Name
3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol
InChi Key
BNDYIYYKEIXHNK-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H15N3O3/c1-21-14-7-12-13(8-15(14)22-2)17-9-18-16(12)19-10-4-3-5-11(20)6-10/h3-9,20H,1-2H3,(H,17,18,19)
SMILES Code
OC1=CC=CC(NC2=C3C=C(OC)C(OC)=CC3=NC=N2)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 297.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: An R, Hagiya Y, Tamura A, Li S, Saito H, Tokushima D, Ishikawa T. Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro. Pharm Res. 2009 Feb;26(2):449-58. doi: 10.1007/s11095-008-9738-5. PubMed PMID: 18841444. 2: Slon-Usakiewicz JJ, Dai JR, Ng W, Foster JE, Deretey E, Toledo-Sherman L, Redden PR, Pasternak A, Reid N. Global kinase screening. Applications of frontal affinity chromatography coupled to mass spectrometry in drug discovery. Anal Chem. 2005 Mar 1;77(5):1268-74. PubMed PMID: 15732906. 3: Cetkovic-Cvrlje M, Roers BA, Schonhoff D, Waurzyniak B, Liu XP, Uckun FM. Treatment of post-bone marrow transplant acute graft-versus-host disease with a rationally designed JAK3 inhibitor. Leuk Lymphoma. 2002 Jul;43(7):1447-53. PubMed PMID: 12389628. 4: Ghosh S, Jennissen JD, Liu XP, Uckun FM. 4-[3-Bromo-4-hydroxyphenyl)amino]-6,7-dimethoxyquinazolin-1-ium chloride methanol solvate and 4-[(3-hydroxyphenyl)amino]-6,7-dimethoxy-1-quinazolinium chloride. Acta Crystallogr C. 2001 Jan;57(Pt 1):76-8. PubMed PMID: 11173405. 5: Chen CL, Malaviya R, Navara C, Chen H, Bechard B, Mitcheltree G, Liu XP, Uckun FM. Pharmacokinetics and biologic activity of the novel mast cell inhibitor, 4-(3-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in mice. Pharm Res. 1999 Jan;16(1):117-22. PubMed PMID: 9950289.